Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX AvKARE — Cost of goods sold

Other segment segments

Affordable Medicines
$282.68M+11.9%

Similar metrics at other companies

lululemon athletica logo
LULUProduct costs — Cost of goods sold
$746.45M+14.3%
Wolverine World Wide logo
WWWCorporate — Cost of goods sold
-$700K-200%
Wolverine World Wide logo
WWWOther — Cost of goods sold
$1.3M0.0%
Micron Technology logo
MUAEBU — Cost of goods sold
$859M+4.8%
Micron Technology logo
MUCDBU — Cost of goods sold
$1.46B+51.1%
Micron Technology logo
MUCMBU — Cost of goods sold
$2B+52.0%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Three Months Ended June 30, 2026Affordable Medicines (1)SpecialtyAv KARECorporateand OtherTotal Company
Net revenue$489,913$149,295$156,989$796,197
Cost of goods sold282,68448,265130,740461,689
Gross profit207,229101,03026,249334,508
Selling, general and administrative42,36740,09516,91349,347148,722
Research and development33,0235,99439,017
Intellectual property legal development expenses2,002852,087
Acquisition costs7,6007,600
Restructuring and other charges554554

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold?
Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — cost of goods sold of $130.74M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold changed year-over-year?
Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold increased by 0.7% year-over-year, from $129.81M to $130.74M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold has grown at a 20.6% compound annual growth rate (CAGR), from $282.87M to $597.94M.
What does avkare — cost of goods sold mean?
Includes the direct costs attributable to the production and procurement of pharmaceuticals sold by the AvKARE segment, such as raw materials, manufacturing labor, and distribution logistics. Monitoring this metric is essential for evaluating the segment's production efficiency and direct cost management.

Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — cost of goods sold.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude